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Abstract
Exposure of newborn calves to chronic hypoxia causes pulmonary artery (PA) hypertension and remodeling. Previous
studies showed that the redox-sensitive transcription factor, early growth response-1 (Egr-1), is upregulated in the PA of
chronically hypoxic calves and regulates cell proliferation. Furthermore, we established in mice a correlation between
hypoxic induction of Egr-1 and reduced activity of extracellular superoxide dismutase (EC-SOD), an antioxidant that
scavenges extracellular superoxide. We now hypothesize that loss of EC-SOD in chronically hypoxic calves leads to
extracellular superoxide-mediated upregulation of Egr-1. To validate our hypothesis and identify the signaling pathways
involved, we utilized PA tissue from normoxic and chronically hypoxic calves and cultured calf and human PA smooth
muscle cells (PASMC). Total SOD activity was low in the PA tissue, and only the extracellular SOD component decreased with
hypoxia. PA tissue of hypoxic calves showed increased oxidative stress and increased Egr-1 mRNA. To mimic the in vivo
hypoxia-induced extracellular oxidant imbalance, cultured calf PASMC were treated with xanthine oxidase (XO), which
generates extracellular superoxide and hydrogen peroxide. We found that 1) XO increased Egr-1 mRNA and protein, 2) XO
induced the phosphorylation of ERK1/2 and, 3) pretreatment with an ERK1/2 inhibitor prevented induction of Egr-1 by XO.
siRNA knock-down of EC-SOD in human PASMC also upregulated Egr-1 mRNA and protein, activated ERK1/2, and enhanced
SMC proliferation and reduced apoptosis. We conclude that an oxidant/antioxidant imbalance arising from loss of EC-SOD in
the PA with chronic hypoxia induces Egr-1 via activation of ERK1/2 and contributes to pulmonary vascular remodeling.
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Introduction
Infants, children and adults with chronic lung diseases
complicated by alveolar hypoxia are at risk for developing
pulmonary hypertension, which is associated with a high
morbidity and mortality [1]. Exposure of animals to chronic
hypoxia is a well-established and useful model to interrogate the
mechanisms that may contribute to human disease. Accumulating
evidence indicates that reactive oxygen species including super-
oxide (O2
.2) are important in the pathogenesis of pulmonary
hypertension, including chronic hypoxia-induced pulmonary
hypertension [2,3]. There are a number of known sources of
O2
.2 in the pulmonary artery including NADPH oxidase, the
mitochondrial electron transport chain, uncoupled endothelial
nitric oxide synthase and xanthine oxidase (XO) that have been
implicated in generation of O2
.2 in response to hypoxia [3,4].
There is accumulating evidence that O2
.2 generated specifically in
the extracellular compartment contributes to the development of
pulmonary hypertension. The antioxidant enzyme which defends
against extracellular O2
.2, extracellular superoxide dismutase (EC-
SOD or SOD3), is highly expressed in the pulmonary circulation,
and its level of expression may modulate the development of
pulmonary hypertension. Lung EC-SOD expression and activity
decreases in rodent models associated with oxidative stress,
including hypoxia and bleomycin-induced lung injury, as well as
in the bronchus of humans with end-stage idiopathic pulmonary
arterial hypertension [5–9]. Furthermore, enhancing lung EC-
SOD activity either in genetically engineered mice or with
adenoviral gene delivery protects against pulmonary hypertension
and pulmonary vascular remodeling due to monocrotaline,
bleomycin, or chronic hypoxia [10–12]. Overexpression of EC-
SOD protects by limiting fibrosis and inflammation and prevents
the upregulation of key genes involved in these processes. Among
many redox-regulated genes, the transcription factor, early growth
response-1 (Egr-1) is of interest because we and others have shown
it increases in the lung and pulmonary vascular cells early in
response to hypoxia and activates a number of downstream targets
critical to proliferation, fibrosis and inflammation [10,11,13–19].
Therefore, Egr-1 can play a critical role in pulmonary vascular
remodeling though its regulation in pulmonary hypertension by
ROS is not clearly understood.
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pulmonary hypertension has not been substantially investigated.
Broadly it has been recognized that the neonatal lung is susceptible
to oxidative stress due to the developmental regulation of
antioxidant defenses [20]. The neonatal calf is particularly
susceptible to hypoxia-induced pulmonary hypertension, with
severe inflammation, pulmonary vascular remodeling and pulmo-
nary hypertension, and Egr-1 is increased in the pulmonary artery
in the chronically hypoxic neonatal calf [19]. The calf model is a
useful model not only because of the severe pathology similar to
human disease, but also because of the availability of primary
pulmonary artery cells from the neonatal calf to test mechanisms
responsible for the pathogenesis of pulmonary hypertension. We
hypothesized that loss of EC-SOD specifically within the
pulmonary artery of the newborn calf in response to hypoxia
leads to extracellular superoxide-mediated upregulation of Egr-1.
We utilized PA tissue isolated from normoxic and chronically
hypoxic calves along with cultured calf to test this hypothesis and
investigate the signaling pathway involved in the ROS modulation
of Egr-1. In addition, we also knocked-down EC-SOD in human
PASMC to directly test the contribution of EC-SOD to Egr-1
expression as well as SMC proliferative ability.
Methods
Animal Model and Tissue Harvesting
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. All
animal studies were approved by the Institutional Animal Use and
Care Committees (Colorado State University School of Veterinary
Medicine, Fort Collins, CO (Protocol 10-1927A) or University of
Colorado School of Medicine, Aurora, CO (Protocol #
71108(03)1E). Chronic exposure to hypoxia is a well-established
model of pulmonary hypertension, characterized by elevated
pulmonary artery pressures and pulmonary artery remodeling. In
this study, 1-day-old male Holstein calves (Laluna Dairy Farm,
Fort Collins) were placed in a hypobaric hypoxia chamber at PB
445 mm Hg (simulating 15,000 ft or 12% FIO2) for 14 days along
with age-matched calves maintained in ambient Denver altitude
(PB 640 mm Hg). Tissue from chronically hypoxic calves was
harvested within the chamber under hypobaric hypoxic conditions
while tissue from normoxic calves was obtained in normobaric
atmosphere. Calves were euthanized with an overdose of
pentobarbital sodium (160 mg/kg body weight) and lung tissue
and intraparenchymal proximal pulmonary artery tissue contain-
ing all three layers of the vessel wall were rapidly dissected and
flash frozen. Another pulmonary artery segment was placed in
cold media for preparation of primary vascular cell lines. Tissue
was flash frozen for analysis.
Cell Culture model
To test how extracellular O2
.2 generated in the pulmonary
artery wall can upregulate the redox sensitive transcription factor,
Egr-1, experiments were done with smooth muscle cells (SMC)
isolated from the pulmonary artery of normoxic or chronically
hypoxic calves using an explant technique as previously described
[21]. This cell type was selected as a key cell type implicated in the
pathogenesis of pulmonary hypertension that also expresses Egr-1
[19,22]. Cells were grown in DMEM with 10% bovine calf serum
(Gemini, West Sacramento, CA) and supplemented with Cellgro
1% NEAA (Mediatech, Inc, Manassas, VA), 4 mM Cellgro L-
Glutamine (Mediatech, Inc) and Cellgro pen-strep (100 I.U/mL
pen and 100 mg/mL strep, Mediatech, Inc) and maintained in
humidified incubator at 5% CO2 and 37uC. Cells were used
between passages 4 and 8. The cell culture data, unless specified
otherwise in a particular experiment, is derived from three
separate wells or plates of cells derived from a single chronically
hypoxic calf and performed on a single day to control for day-to-
day variability and enable comparisons between experimental
groups. The experiments were repeated on at least 3 different days
with cells from at least 3 different calves to ensure reproducibility.
The qPCR was also performed in triplicate for each cell isolation.
Human PASMC purchased from Lonza were grown in designated
SMC media (Clonetics LONZA smBm media cat no: CC3181).
Treatment groups
Cells were treated with XO because it is an enzyme known to be
upregulated in the pulmonary circulation in models of pulmonary
hypertension and it is a reproducible method to generate
extracellular O2
.2 in order to study the impact of O2
.2 released
in this particular cell compartment. Cells were treated with XO
dissolved in phosphate buffered saline (PBS) (Sigma, St Louis,
MO) and hypoxanthine (HX) (Sigma) dissolved in 0.1 M sodium
hydroxide (NaOH). The optimal dose of XO and HX was
established with a dose and time response curve. Based on pilot
results, all remaining studies were carried out using cells treated for
1 hour with 8 mU/mL XO and 0.5 mM HX (XO/HX). Control
cells for XO/HX treatment received the vehicles alone (PBS and
0.1 M NaOH). For studies with extracellular antioxidant treat-
ments, cells were pretreated for 30 minutes with 500 U/mL SOD
(Sigma) and/or catalase 600 U/mL (Boehringer Mannheim,
Mannheim, Germany). Catalase was first dialyzed against PBS
for 24 hours in PBS and activity determined as previously
described [23]. Catalase was stored at 220uC until used. For
MAPK inhibitor studies, cells were pretreated for 30 minutes with
the ERK1/2 Inhibitor PD98059 (10 mM, Cell Signaling Danvers,
MA) followed by the 1 hour treatment with XO. One series of
PASMC were exposed in sealed humidified gas chambers to 21%
or 1% oxygen tension with 5% CO2 and balanced N2 for 4 and
24 hours, as previously described, to evaluate the relative impact
of hypoxia on Egr-1 expression and extracellular O2
.2 release
compared to XO/HX-treated cells [10–12]. An additional series
of cells were treated for 2 hours with low dose (0.25 mM) or high
dose (250 mM) antimycin A, an inhibitor of the mitochondrial
electron transport chain, to generate endogenous O2
.2. Antimycin
A was dissolved in DMSO and the appropriate vehicle was used
for control conditions.
siRNA transfection
An siRNA targeting EC-SOD and a non-targeting siRNA were
transfected into human PASMC (Lonza Walkersville, Walkersville,
MD) using the siPORT NeoFX transfection reagent (Ambion).
Cells (12610
5) in a 6-well plate, were transfected with a final
concentration of 5 nM of non-targeting (negative control, siNEG))
or siRNA targeting EC-SOD, (siEC-SOD). The manufacturer’s
suggested protocol of a reverse transfection was followed.
Transfected cells were then harvested after 48 h for mRNA or
protein analysis. After every transfection, the EC-SOD knockdown
was confirmed by qPCR.
mRNA isolation from calf PA and cultured cells
For pulmonary artery segments, the fibrous tissue was first
pulverized using a mortar and pestle on liquid nitrogen to facilitate
homogenization. Cells, 4610
4 per well, were seeded in a 6 well
plate (Corning, Lowell MA) and allowed to grow for 48 hours
prior to treatment. RNA was isolated from tissue using TRIzol
(Invitrogen, Carlsbad, CA) and from cells using the RNeasy Plus
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instructions. The concentration and purity of each total RNA
sample was determined by the NanoDropH ND-1000 spectropho-
tometer (NanoDrop, Wilmington, DE). The integrity of total RNA
samples was examined by 2100 Bioanalyzer and the RNA 6000
Nano Kit (Agilent Technologies).
mRNA analysis by real time RT-PCR (qPCR)
RNA (1 mg per reaction) was reverse transcribed with the
Maxima First Strand cDNA synthesis kit (Fermentas International
Inc, Glen Burnie, MD). PCR was performed on the MyiQ
Detection System (Bio-Rad, Hercules, CA) with the RT
2 Real-
Time SYBR Green/Fluorescein PCR master mix (SABiosciences,
Frederick, MD). Reactions were run in triplicate and results
analyzed by the 2 (2delta delta CT) Method, normalizing the
gene copy numbers to hypoxanthine-guanine phosphoribosyl-
transferase (HPRT). Data are expressed in figures as either actual
copies of Egr-1/HPRT or, to more easily visualize fold change in
certain experiments, Egr-1/HPRT normalized to the mean
expression of the control group. Primers for calf tissue were
designed with NCBI Primer-BLAST software. Primers used were
Egr-1 forward: CCTTCAG TACCCACCTCCTG Egr-1 reverse:
AGGGCTTCTGATCTGGTGTG. HPRT forward: CCAAA-
GATGGTCA AGGTTGC HPRT reverse: GGGCATATCC-
CACAACAAAC. Human Egr-1 and GAPDH primers were
purchased from SABiosciences. For human EC-SOD mRNA
analysis, Taqman EC-SOD primers were purchased along with
the corresponding GAPDH primers and qPCR performed with
Taqman master mix according to instructions (Applied Bioscienc-
es).
Protein isolation
Pulverized lung or pulmonary artery tissue was homogenized in
RIPA buffer (Sigma) containing protease (Sigma) and phosphatase
(Thermo Scientific, Rockford, IL) inhibitors and centrifuged to
remove cellular debris. For total cell lysates from cultured cells,
5.0610
5 cells were seeded in 100 mm dishes (Corning) and
allowed to grow for 48 hours prior to treatment. After appropriate
treatment, media was removed and plates placed on ice, cells
washed 26PBS and then lysed in RIPA buffer (Sigma) containing
protease (Sigma) and phosphatase (Thermo Scientific) inhibitors.
Cells were scraped and placed in 280uC overnight followed by
sonification and centrifugation at 4uC degrees to collect the
supernatant. Protein concentration was determined using the
Pierce 660 nm protein assay reagent (Thermo Scientific). Nuclear
protein was extracted from calf PASMC (1610
6 cells per
condition) using NE-PER Nuclear and Cytoplasmic Extraction
Reagents according to product instructions (Pierce Biotechnology,
Rockford, IL).
Western blot analysis
For Western blot analysis with the phosphoERK1/2 and total
ERK1/2 antibodies, 20 mg human or calf total PASMC protein
was loaded on a 4–12% Bis-Tris Gel (Invitrogen, Carlsbad, CA)
and protein separated by gel electrophoresis. Proteins were
transferred to PDVF membranes using the semi-dry method
(Invitrogen). Blots were blocked with 5% milk in Tris Buffered
Saline with 0.05% Tween 20 (TBST) and probed with the primary
monoclonal mouse phospho-p44/42 MAPK antibody (Cell
Signaling, 1:1000) overnight at 4uC followed by an anti-mouse
HRP-conjugated secondary antibody (Millepore, Billerica, MA).
Blots were developed with Enhanced Chemiluminescence (ECL)
plus (Thermo Scientific) and then stripped with Restore Plus
Western Blot Stripping Buffer according to kit instructions
(Thermo Scientific) and reprobed with rabbit monoclonal Total
ERK antibody (Cell Signaling, 1:1000), for normalization: Bands
were quantified by densitometry and expressed as the ratio of
phosphoERK/totalERK. Blots from human PASMC total cell
lysates were also probed with polyclonal rabbit anti-Egr-1 (Cell
Signaling, 1:500), cyclin D1 (Cell Signaling , 1:1,000) and ß-actin
as a loading control. For calf PASMC, to reduce non-specific
binding by the Egr-1 antibody, likely due to poor cross-reactivity
with the anti-human Egr-1 antibody, 25 mg nuclear extracts were
used instead for Western blot. Equal nuclear protein loading was
confirmed by Ponceau S staining (Millipore). For the Western blot
with protein from pulmonary artery or lung tissue, 20–100 mg of
protein homogenate was loaded on the gel as well as 1 mg purified
bovine EC-SOD protein as a positive control. The blot was
probed overnight at 4uC with 1:1,000 rabbit anti-human EC-SOD
ab in 5% milk, which recognizes bovine EC-SOD (purified EC-
SOD and EC-SOD antibody kindly provided by Tim Oury, MD,
PhD, University of Pittsburgh). Western blots for PA protein were
also probed with antibodies against Cu,Zn SOD (Abcam, 1:2,000)
Mn SOD (Millipore, 1:1,000), and ß-actin in protein homogenates
from normoxic and chronically hypoxic calves.
Reactive oxygen species measurements
2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-
carboxanilide, disodium salt (XTT) (Sigma) was used to detect
extracellular O2
.2 generated in response to XO/HX or
hypoxia in cultured calf PASMC. SMC (3610
4), were plated
in triplicate in a 96 well plate in phenol free medium
containing the supplements as described above. Cells were
grown for 48 hours and prior to treatment, cells were washed
with 16PBS and replaced with fresh phenol-free medium. To
measure the change in extracellular O2
.2 generated by XO/
HX, XTT (100 mm) was added to the cells along with either
XO/HX or vehicle. The change in absorbance at 470 nm was
read by a Biorad 680 microplate reader (Biorad, Hercules, CA)
at 1 hr following XO/HX. One set of cells were pre-treated for
30 minutes with 500 U/mL SOD (Sigma) prior to the addition
of XO/HX. The experiment was repeated three times. Using
the extinction coefficient of 21600 M
21 cm
21 (XTT), the
superoxide flux was calculated and data expressed as rate of
superoxide flux (MNs
21). Hydrogen peroxide was measured in
calf PASMC treated with 1 hour of XO/HX using a
fluorometric assay as described by Hyslop et al [24] and the
rate of H2O2 production was expressed in MNs
21.B r i e f l y ,i n
this assay, cells are rinsed and incubated with phenol red-free
buffer containing horseradish peroxidase (HRP, 1.6 mM),
HEPES buffer, NaHCO3 (60 mM) and para-hydroxyphenyl
acetic acid (pHPA, 95 mg/mL) for two hours. The reaction of
H2O2 with HRP forms compound I, which then oxidizes
pHPA and results in the formation of a fluorescent dimer
product detectable by a fluorometric plate reader (polarstar
Omega, BMG Labtech) [24].
SOD Activity assay
Pulverized lung and pulmonary artery tissue (300 mg) were
homogenized in 10 volumes of ice-cold buffer (50 mM potassium
phosphate, pH 7.4, with 0.3 M KBr, 0.05 mM phenylmethylsul-
fonyl flouride, and 3 mM diethylene-triaminepentaacetic acid) and
centrifuged to remove cellular debris. For the pulmonary artery
homogenates, EC-SOD was separated from intracellular SOD
(Cu,Zn SOD and Mn SOD) using a concanavalin A column
(Pierce,Rockford,Illinois) as previously described [25]. Briefly,
pulmonary artery homogenates were applied to the column.
Intracellular SODs were collected by washing the column with
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0.25 M NaCl). The EC-SOD fraction was eluted with 3 mL
50 mM HEPES, pH 7.0 with 0.25 M NaCl with 1 M alpha-
methylmannoside, final pH 5. The EC-SOD fraction was
concentrated 10-fold by centrifuging with a centriprep concentra-
tor (Amicon-ultracel-10K, Millipore) at 4uC for 60 minutes. EC-
SOD and intracellular SOD separation was confirmed by Western
blot, as described above, and activity levels were measured using
the SOD assay kit-WST (Dojindo Molecular Technologies,
Maryland, USA). This kit utilizes a water-soluble tetrazolium salt,
WST-1 [2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfo-phenyl)-
2H-tetrazolium, monosodium salt], to produce a water-soluble
formazan dye upon reduction with a superoxide anion, detectable
by a colorimetric assay. A standard curve was linear between SOD
concentrations of 0.1 to 5 U/mL. SOD activity data were
expressed as units of SOD activity per gram of tissue.
GSH/GSSG assay
The GSH/GSSG ratio was measured as a marker of oxidative
stress in PA tissue following chronic hypoxia as previously
described [26,27]. Briefly, cow PA tissue (50 mg) was homoge-
nized in MES (Morpholino ethanesulfonic acid) (2:1, w/v) at 4uC
and centrifuged at 12,000 g. Total glutathione was determined
after reducing GSSG to GSH with glutathione reductase by the
method of Anderson [26]. GSSG alone was determined by
incubating the sample with 2-vinyl pyridine to eliminate the GSH.
The glutathione concentrations were normalized to the protein
content in the sample as assayed by the Pierce 660 nm protein
assay reagent (Thermo Scientific) and the ratio of GSH/GSSG
was calculated.
Cell Proliferation and Apoptosis Assays
These assays were carried out using human PASMC. Cell
proliferation was measured by MTS assay using CellTiter 96
AQueous One Solution (Promega, Madison, WI). Twenty-dour
hours after transfection with siRNA, ,2000 cells were plated in a
96-well plate and twenty microliters of 3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
inner salt (MTS) was added to the wells on consecutive dates.
MTS is bio-reduced by cells into a colored formazan product that
reduces absorbance at 490 nm. Plates were read at 24 and
48 hours using a BioTek MODEL plate reader (Winooski, VT)
two hours after MTS reagent was added. Apoptosis was assayed
forty-eight hours after siRNA transfection. Phosphatidylserine
externalization (a marker of early apoptosis) was analyzed using
the Guava Nexin reagent. Cells were counted following staining
with Guava ViaCount reagent (Millipore, Billerica, MA) and the
amount of apoptosis determined using Guava Nexin reagent
(Millipore). Samples were run on a Guava EasyCyte Plus flow
cytometer (Millipore). Experiments were done in triplicate.
Statistical Analysis
Data are expressed as means 6 SE. Unpaired t-test analysis or
one-way Anova with Bonferroni post-hoc analysis was performed
using Prism software (GraphPad, San Diego, CA, USA). Statistical
significance was defined as p,0.05.
Results
A. From experiments with in vivo tissue samples
Chronic hypoxia decreases EC-SOD activity in the
pulmonary artery of the neonatal calf. We speculated that
chronic hypoxia would lead to a loss of EC-SOD activity in the
pulmonary artery of the chronically hypoxic neonatal calf, similar
to our observation in the lungs of weanling mice exposed to
hypoxia [10]. We separated the intracellular SODs from
extracellular SOD in bovine pulmonary artery homogenates
using a concavalin A column and measured the activity in each
fraction. Extracellular SOD activity in the pulmonary artery was
decreased by 36% following 14 days of chronic hypoxia compared
to normoxic sample (Figure 1A). In contrast, the intracellular
SOD activity levels increased 7.6-fold (Figure 1B). Furthermore,
while extracellular SOD comprised 60% of total SOD activity
under normoxic conditions, it only accounted for 7.5% of total
SOD activity by the end of the hypoxic exposure (Figure 1C). We
performed Western blot analysis on the two fractions of SOD to
confirm that the Cu,Zn SOD (SOD1) and Mn SOD (SOD2) were
only detectable in the intracellular fraction (IC-SOD), while EC-
SOD (SOD3) was almost exclusively bound to the concavalin A
column based on its glycosylated state, and eluted in the
extracellular SOD fraction. (Figure 1D) Further, we performed
several comparison measurements of SOD activity and EC-SOD
expression in the mouse and calf lung tissue to corroborate the low
enzymatic defenses against extracellular O2
.2 measured in the
neonatal calf. We observed the total SOD activity was significantly
lower in two week old calf lungs compared with immature (four
week old) mouse lungs (Figure S1A). Furthermore, when we
performed Western blot analysis using 25–100 mg protein
prepared from peripheral calf lung or pulmonary arteries, we
were unable to detect any signal with an EC-SOD antibody. We
have previously observed that EC-SOD is easily detectable in
25 mg mouse lung, and we used 1 mg purified bovine EC-SOD
(kindly provided by Dr. Tim Oury, University of Pittsburgh.) as a
positive control (Figure S1B). Therefore, any small change in
SOD activity level in calf is crucial as it is more prone to oxidative
stress. Despite the increase in intracellular SOD, there was no
significant change in Cu,Zn or Mn SOD protein expression
(Figure S1C). As there was a significant decrease in EC-SOD in
calf PA after chronic hypoxia, we carried out further experiments
with calf PA to study the role of ECSOD and the impact of
chronic hypoxia.
Oxidative stress is increased in the pulmonary artery of
chronically hypoxic neonatal calves. Since EC-SOD activity
is markedly decreased in the tissues of chronic hypoxic calves, it
could trigger oxidative stress. Oxidative stress in the pulmonary
artery was evaluated by determining the ratio of reduced to
oxidized glutathione (GSH/GSSG) in the calf PA following 2
weeks of hypoxia. During periods of increased oxidative stress,
GSSG will accumulate and the ratio of GSH to GSSG will
decrease. Therefore, the determination of the GSH/GSSG ratio is
a general indicator of oxidative stress in cells and tissues. We
observed that the ratio of GSH/GSSG in calf PA decreased by
50% with hypoxia (Figure 2). The ratio was low in calf PA
compared to our previously published findings in the mouse lung
[10].
The redox sensitive transcription factor, Egr-1, is
increased in the pulmonary artery of the chronically
hypoxic neonatal calf. We have previously reported that the
level of EC-SOD activity in the lung modulates the hypoxic
upregulation of Egr-1 in mice [10]. In addition, it has previously
been reported that Egr-1 is highly expressed in the pulmonary
artery adventitia of chronically hypoxic calves and Egr-1
contributes to hypoxia-induced cyclin D1 expression and
fibroblast proliferation [10]. To confirm the vascular changes in
Egr-1, we compared the mRNA expression of Egr-1 in lung and
intraparenchymal proximal pulmonary artery of chronically
hypoxic calves compared to age-matched normoxic calves. We
found that Egr-1 mRNA expression did not increase in the lung
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pulmonary artery of chronically hypoxic calves (Figure 3).
B. From in vitro experiments with calf PASMC cells
Extracellular reactive oxygen species upregulate Egr-1 in
pulmonary artery smooth muscle cells (PASMC). To
evaluate whether the increased Egr-1 expression detected in the
pulmonary artery of chronically hypoxic calves could be directly
mediated by extracellular ROS, we performed a series of
experiments in SMC treated with XO+HX as an exogenous
source of ROS. A dose response curve with a concentration of XO
between 1–16 mU/mL and a time course between 30 minutes to
4 hours was initially performed to select the experimental
conditions (Figure S2). Based on these pilot studies, we selected
one hour incubation with 8 mU/mL XO and 0.5 mM HX for
subsequent experiments. This experimental condition significantly
increased Egr-1 mRNA expression in SMC (Figure 4A).
XO generates extracellular O2
.2, which rapidly dismutates to
H2O2, though XO can also generate H2O2 directly, depending on
conditions such as pH or oxygen concentration [28–30]. In our
experimental conditions, we detected an increase in extracellular
O2
.2 flux when cells were treated with XO/HX for 1 hour, as
shown by the SOD-inhibitable reduction of XTT, which
specifically reflects extracellular O2
.2 generation (Figure 4B).
H2O2 production was also significantly elevated following a 1 hour
treatment with XO/HX while H2O2 was below the level of
Figure 1. EC-SOD is decreased in the pulmonary artery in response to chronic hypoxia. In pulmonary artery tissue homogenates from
two-week old chronically hypoxic (Hypo) and age-matched normoxic (Norm) control calves, extracellular SOD was separated from intracellular SODs
(Cu,Zn SOD or SOD1 and Mn SOD or SOD2) using a concavalin A sepharose column, based on EC-SOD’s predominantly glycosylated state that
enables it to bind to the column and thus separate intracellular SODs (nonbound) from extracellular SOD (bound, then eluted) fraction. SOD activity
was measured in each fraction using the SOD assay kit-WST. A. EC-SOD activity. B. Intracellular SOD (IC-SOD) activity. C. The percent of total SOD
activity attributable to EC-SOD. Data expressed as mean 6 SEM. *p,0.05 vs. Norm; n=5. D. Western blot analysis of Cu,Zn SOD, Mn SOD and EC-SOD
in the intracellular and extracellular fractions to confirm adequate separation of IC-SOD from EC-SOD. Lane 1 and 2 are the intracellular fractions from
the two normoxic calves and the corresponding extracellular fraction is shown in Lanes 3 and 4.
doi:10.1371/journal.pone.0027531.g001
Figure 2. The GSH/GSSG ratio is decreased in the pulmonary
artery of the chronic hypoxic calf (Hypo) compared to the
normoxic control calf (Norm). A. GSH and total glutathione levels
were measured and data expressed as the ratio of GSH to GSSG. Data
expressed as mean 6 SEM. *p,0.05 vs. Norm; n=4.
doi:10.1371/journal.pone.0027531.g002
Figure 3. The redox-sensitive transcription factor Egr-1 is
increased in the pulmonary artery of chronically hypoxic
calves (Hypo) compared to age-matched normoxic control
calves (Norm). Egr-1 mRNA expression was measured by qPCR in the
pulmonary artery of 2 week old chronically hypoxic calves compared to
age-matched normoxic control calves . Data are expressed as copies of
Egr-1 per copy HPRT, mean 6 SEM. *p,0.05 vs. Norm; n=4–5.
doi:10.1371/journal.pone.0027531.g003
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of H2O2 was lower than the production of O2
.2 indicating that
extracellular H2O2 was being rapidly removed by the cells, likely
through GSH (Figure 4C). Compared to PASMC treated with
XO/HX, exposure of cells to hypoxia produced a significantly
smaller rise in Egr-1 mRNA (Figure 5A) as well as less
extracellular O2
.2 production (Figure 5B). Low dose antimycin
A, at a dose known to generate endogenous ROS due to inhibition
of complex III of the mitochondrial electron transport chain, did
not upregulate Egr-1, though high dose antimycin A did result in
an increase in Egr-1 mRNA (Figure 5C).
Xanthine oxidase-derived extracellular reactive oxygen
species upregulated Egr-1 via the activation of ERK1/2 in
pulmonary artery smooth muscle cells. MAPK/ERK
signaling pathways have been shown to regulate Egr-1, and
many MAPK enzymes are redox sensitive. To determine if
Figure 4. Xanthine oxidase upregulates Egr-1 in calf pulmo-
nary artery smooth muscle cells. (A) Egr-1 mRNA expression was
measured by qPCR in PASMC exposed to xanthine oxidase (XO- 8 mU/
mL) and hypoxanthine (0.5 mM) at 37uC for 1 hour (XO). Data are
expressed as fold change in Egr-1/HPRT relative to vehicle treated cells
and presented as mean 6 SEM. *p,0.05 vs. vehicle treated cells. B.
Extracellular O2
.2 was measured by the SOD-inhibitable reduction of
XTT in XO+hypoxanthine-treated (XO), and vehicle-treated smooth
muscle cells with and without SOD (500 U/mL). 20,000 cells were
treated in a final volume of 150 mL and exposed to XTT for 1 hour at
37uC and pH 7.4. An extinction coefficient of 21600 M
21 cm
21 (XTT)
was used to calculate O2
.2 flux and data expressed in MNs
21.* p ,0.05
vs. vehicle-treated cells, n=3. C. H2O2 was measured with a standard
fluorometric assay utilizing in which H2O2 reacts with HRP to forms
compound I, which subsequently oxidizes pHPA to its dimer form which
can be detected on a fluorometer. Experiments were performed with
30,000 cells per well and a final volume of 150 mL for 2 hours at 37uC
and pH 7.4 and H2O2 flux expressed in MNs
21.* p ,0.05 vs. vehicle-
treated cells, n=3. Data expressed as mean 6 SEM.
doi:10.1371/journal.pone.0027531.g004
Figure 5. Exposure of calf PASMC to hypoxia resulted in less
induction of Egr-1 and less extracellular superoxide generation
than XO. A. Egr-1 mRNA expression in calf PASMC exposed in sealed
humidified gas chambers with 21% or 1% O2 plus 5% CO2 and balanced
N2 at 37uC for 4 and 24 hours and shown compared to XO/HX
treatment for 1 hour (XO). B. Extracellular O2
.2 production in PASMC
exposed to XO/HX (XO) or hypoxia as described above. 20,000 cells
treated in a final volume of 150 mL were exposed to XO/HX (XO) for 1 or
4 hours or hypoxia for 4 hours at 37uC and pH 7.4 in the presence of
XTT. An extinction coefficient of 21600 M
21 cm
21 was used to calculate
O2
.2 flux (M-s
21). C. Egr-1 mRNA expression in calf PASMC exposed to
antimycin A to increase endogenous ROS generated in the mitochon-
dria. 20,000 cells were exposed to 0.25 mM or 250 mM antimycin A for
2 hours at 37uC. All data expressed as mean 6 SEM. *p,0.05 vs.
vehicle-treated cells, n=3.
doi:10.1371/journal.pone.0027531.g005
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.2,o rH 2O2 arising from the dismutation of O2
.2,
induced the upregulation of Egr-1 via MAPK, we first evaluated
whether XO/HX treatment resulted in phosphorylation of
ERK1/2. Treatment with XO/HX led to phosphorylation of
ERK1/2 (Figure 6A) in PASMC. Pretreatment with the ERK1/2
inhibitor, PD98059 (10 mM) attenuated the XO/HX-mediated
upregulation of Egr-1, as measured by qPCR (Figure 6B). We
also detected an increase in Egr-1 protein levels in the nuclear
protein of cells exposed to XO/HX that was blocked by the
PD98059. (Figure 7B). The combined pretreatment of cells with
SOD and catalase reversed both XO/HX-mediated ERK1/2
phosphorylation (Figure 6C) as well as upregulation of Egr-1
mRNA and protein (Figure 6D and 7B). Catalase also
significantly attenuated the upregulation of Egr-1 by XO/HX,
while pretreatment with SOD alone did not prevent the
upregulation of Egr-1 (Figure S3). These data cumulatively
demonstrate a loss of EC-SOD and increased oxidative stress in
the PA of chronically hypoxic calves and define a role for
extracellular ROS in the upregulation of Egr-1 via the activation
of EKR1/2 signaling in the pulmonary circulation.
Xanthine oxidase treatment of PASMC isolated from
chronically hypoxic calves with lower PA EC-SOD activity
augmented the upregulation of Egr-1 mRNA and
protein. Upon completing studies that tested the impact of
extracellular O2
.2 on Egr-1 expression, we performed a final series
of experiments in PASMC isolated from normoxic and chronically
hypoxic calves and in human PASMC following siRNA silencing
of EC-SOD. These experiments were designed to confirm the
impact of the level of EC-SOD expression on Egr-1 expression in
the in vitro model and tested the impact of EC-SOD activity on
SMC growth characteristics. The PASMCs isolated from
chronically hypoxic calves showed a more significant increase in
Egr-1 mRNA in response to XO/HX (Figure 7A) compared to
cells isolated from normoxic calves. PASMC from three normoxic
calves and three hypoxic calves were simultaneously passaged and
treated with XO/HX to minimize experimental variability. Cells
from both normoxic and hypoxic calves increased nuclear Egr-1
protein expression following XO/HX, with a higher signal
detectable in cells isolated from a chronically hypoxic calf
compared to cells isolated from a normoxic calf. Pretreatment
with SOD+catalase or ERK inhibition attenuated the increase in
XO/HX induced Egr-1 protein expression (Figure 7B). Equal
loading in the nuclear extracts was confirmed via Ponceau S stain
(Figure S4).
C. From in vitro experiments with human PASMC cells
EC-SOD silencing in human PASMC by siRNA
transfection augmented Egr-1 mRNA and protein
expression. We then performed additional experiments with
human PASMC to confirm the impact of EC-SOD on Egr-1
expression. We selected human PASMC because these cells
express high levels of EC-SOD at baseline, thus knock-down of
EC-SOD would have a more significant impact than in the calf
cells with low EC-SOD expression levels at baseline. Human
PASMC were transfected with human EC-SOD siRNA (siEC-
SOD) or the negative control siRNA vector (siNEG), and EC-
SOD mRNA and protein was measured. We first confirmed that
we significantly knocked down EC-SOD mRNA (Figure 8A) and
protein (Figure 8C) in human PASMC with siRNA treatment.
Knock down of EC-SOD in human PASMC increased Egr-1
mRNA and protein, as measured by qPCR and Western blotting
respectively. (Figure 8B and 8C) Since activated ERK1/2 is
implicated in Egr-1 expression, and Egr-1 can promote cell
proliferation by increasing cyclin D1, we measured
phosphorylated and total ERK1/2 as well as cyclin D1 protein
expression. Knock down of EC-SOD resulted in increased
phosphorylated ERK1/2/total ERK1/2 and increased cyclin
D1 protein levels (Figure 8C).
EC-SOD silencing in hPASMC by siRNA transfection led
to increased cell proliferation and attenuated cell
apoptosis. Pulmonary vascular cells isolated from humans
with PAH or animals with experimental PH exhibit increased
cell proliferation and decreased cell apoptosis. To evaluate the
impact of EC-SOD on PASMC growth characteristics, we
Figure 6. ROS derived from xanthine oxidase increase Egr-1 expression through ERK1/2 signaling. Calf PASMC were treated with XO
(8 mU/mL) and hypoxanthine (0.5 mM) for 1 hour (XO) and protein was isolated for Western blot analysis. A. Blots were probed with antibodies
against phosphorylated ERK1/2 (pERK) and total ERK1/2 (tERK) Each panel shows representative lanes from a single immunoblot as well as the
densitometry data representing the ratio of the phosphorylated to total ERK1/2. B. Calf PASMC were pretreated with the MAPK/ERK1/2 inhibitor
PD98059 (10 mM) for 30 min followed by either XO/HX (XO) or vehicle control. mRNA was isolated and analyzed by qPCR for Egr-1 expression relative
to HPRT. C. Calf PASMC were pretreated with CuZn SOD (500 U/mL) and catalase (600 U/mL) for 30 minutes prior to XO (8 mU/mL) and
hypoxanthine (0.5 mM). Total protein was subjected to Western blot analysis for phosphorylated ERK1/2 (pERK) and total ERK1/2 (tERK). The band
intensities were quantified by densitometry and normalized to that of vehicle. D. PASMC were pretreated with CuZn SOD (500 U/mL) and catalase
(600 U/mL) for 30 minutes prior to XO (8 mU/mL) and hypoxanthine (0.5 mM). mRNA was isolated and analyzed by qPCR for Egr-1 expression relative
to HPRT. All data expressed as mean 6 SEM. *p,0.05 vs. vehicle treated cells;
#p,0.05 vs. 1 hour XO-treated cells; n=3.
doi:10.1371/journal.pone.0027531.g006
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down of EC-SOD. After siRNA treatment to knock down EC-
SOD, there was significant increase in cell proliferation
(Figure 8D). We then measured the apoptotic status of cells
after knock down of EC-SOD by flow cytometry. As shown in
Figure 8E, inhibition of EC-SOD led to a significant decrease in
the cell apoptotic index. These indicate that depletion of EC-SOD
in human PASMC results in increased cell survival and
proliferation.
Discussion
Understanding the molecular mechanism that induces pulmo-
nary hypertension in neonates is important for the development of
improved therapeutics. In this current study, we used the
chronically hypoxic calf model of pulmonary hypertension to
evaluate the activity of EC-SOD in a severe neonatal disease
model and to better understand the role for extracellular O2
.2 in
the upregulation of Egr-1, a redox sensitive transcription factor
implicated in vascular remodeling. We tested the hypothesis that
loss of EC-SOD in chronically hypoxic calves leads to extracellular
O2
.2 -mediated upregulation of Egr-1 via activation of MAPK
pathways. We tested tissue from chronically hypoxic calves to
demonstrate the decrease in EC-SOD in the pulmonary artery in
vivo and then treated isolated pulmonary vascular smooth muscle
cells with xanthine oxidase to show that ROS generated outside
the cell could upregulate Egr-1 via activation of MAPK/ ERK1/
2. We used human PASMC following siRNA knock-down of EC-
SOD to confirm the impact of EC-SOD expression on Egr-1
expression and SMC proliferative ability. Our data provide new
insight into the importance and targets of EC-SOD and
extracellular O2
.2 in chronic hypoxic pulmonary hypertension.
We previously reported that EC-SOD activity is impaired
following exposure to chronic hypoxia, and overexpression of lung
EC-SOD in two murine models of pulmonary hypertension
protected against pulmonary vascular remodeling and prevented
the early upregulation of the redox sensitive transcription factor,
Egr-1 [10,11]. In this study, we report that total SOD activity
levels in the calf lung and pulmonary artery were very low
compared to the mouse lung, and extracellular SOD activity
decreased in the pulmonary artery of calves exposed to 2 weeks of
chronic hypoxia. The low SOD activity level measured in the calf
pulmonary artery tissue was also substantially less than published
activity levels reported for baboon and human pulmonary artery;
though we report, similar to the baboon and human, that EC-
SOD activity accounted for the majority of the total SOD activity
in the pulmonary artery under normal conditions [31]. The low
activity levels of total SOD may be in part due to the young age of
the calves, as lung antioxidant defenses are known to be low early
in life and increase in the perinatal period to prepare for the
relative hyperoxia of room-air breathing. Consistent with this, we
previously reported in the developing rabbit that EC-SOD activity
in the lung increased during the first month of life [25]. Several
pieces of data support the premise that the low SOD activity is
associated with an increase in oxidative stress in the pulmonary
artery of the chronically hypoxic calf. The ratio of GSH/GSSG
was low in the calf pulmonary artery and decreased further with
hypoxia. This result is similar to our published observation in mice
in which the GSH/GSSG ratio decreased by 50% in response to
hypoxia [10]. In chronic hypoxic mice, where we were able to
examine a time-course, we had reported an early increase in EC-
SOD expression and activity, which may reflect an adaptive
response to combat increased oxidant stress [22]. Interestingly, in
this study, we measured an increase in intracellular SOD (IC-
SOD) activity in the calf PA at 2 weeks of hypoxia. This may also
be adaptive in response to increased intracellular oxidative stress.
It is possible that intracellular SOD activity would decrease over
time, as we observed in the lung of chronically hypoxic mice over a
5 week period, but the large animal models are limited by cost and
the longer exposures were not feasible. The loss of EC-SOD
activity was even more pronounced when considered as the
percentage of total SOD activity, decreasing its contribution to
total SOD activity from 60% to less than 10%. We speculate that
an increased susceptibility to oxidative stress due to the low total
SOD activity along with a further loss of extracellular EC-SOD
could contribute to the significant remodeling in the medial and
adventitial layer of the pulmonary arteries observed in the
neonatal calf compared to the modest vascular remodeling
characteristic of chronically hypoxic mice [19,32–35].
To test the impact of extracellular O2
.2on Egr-1 expression in
PASMC, we treated cells with XO, as an enzymatic source of
O2
.2. This exogenous model has potential relevance to the in vivo
setting, as XO is upregulated in the hypoxic pulmonary circulation
and can contribute to pulmonary hypertension [4,36–38]. A key
Figure 7. PASMC isolated from chronically hypoxic calves had
a more marked upregulation of Egr-1 in response to xanthine
oxidase compared to cells isolated from normoxic calves. A.
PASMC isolated from three chronically hypoxic calves and three
normoxic age-matched control calves were treated simultaneously
with xanthine oxidase (8 mU/mL) and hypoxanthine (0.5 mM) at 37uC
for 1 hour (XO). Egr-1 mRNA expression was measured by qPCR and
expressed as fold change in Egr-1/HPRT relative to the vehicle-treated
PASMC isolated from normoxic calves. Data are presented as mean 6
SEM. *p,0.05 vs. vehicle treated cells. B. For protein analysis, PASMC
(1610
6 cells per plate) isolated from a chronically hypoxic calf and a
normoxic age-matched control calf were treated simultaneously with
xanthine oxidase (8 mU/mL) and hypoxanthine (0.5 mM) at 37uC for
1 hour (XO) with and without a 30 minute pretreatment with either
Cu,Zn SOD (500 U/mL) and catalase (600 U/mL) or with the MAPK/
ERK1/2 inhibitor PD98059 (10 mM). Nuclear protein was isolated using
Thermo-Scientific NE-PER Nuclear and Cytoplasmic Extraction Reagents,
and 25 mg was loaded on a gel for Western blot analysis with the Egr-1
antibody (1:1,000). Ponceau S staining was performed on the gel to
confirm protein equal loading. (see Figure S4).
doi:10.1371/journal.pone.0027531.g007
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generation of extracellular O2
.2 by XO in smooth muscle cells
strongly upregulated Egr-1 mRNA and protein expression.
Furthermore, cells isolated from chronically hypoxic calves had
a more marked response to XO than cells isolated from normoxic
calves. Since the SMC are a major source of vascular EC-SOD
and we detected less EC-SOD in the pulmonary artery of
chronically hypoxic calves, we speculate that the loss of EC-SOD
Figure 8. siRNA-mediated knock down of EC-SOD in human pulmonary artery smooth muscle cells increased Egr-1 mRNA and
protein and promoted a pro-proliferative and anti-apoptotic phenotype. Human PASMC were transfected with human EC-SOD siRNA (siEC-
SOD) or the negative control siRNA vector (siNEG) and experiments were performed 48 hours later. A. EC-SOD mRNA expression expressed relative to
GAPDH to test the extent of knock-down of EC-SOD with siRNA. B. Fold change in Egr-1 mRNA expression expressed relative to GAPDH in human
PASMC treated with siEC-SOD compared to cells treated with siNEG. Data are presented as mean 6 SEM. *p,0.05 vs. siNEG. C. Western blot analysis
in total cell lysates from human PASMC treated with siEC-SOD or siNEG. The blots were probed sequentially with the human EC-SOD antibody
(1:1,000), Egr-1 antibody (1:500) cyclin D1 and ß-actin (1:1,000) to confirm equal protein loading. Blots were also probed with the phosphorylated
ERK1/2 and total ERK1/2 antibodies (1:1,000). Densitometry shows fold change in EC-SOD, Egr-1 or cyclin D1 relative to ß-actin and fold change in
phosphorylated relative to total ERK1/2 (n=2). D. Cell proliferation measured by MTS assay. Experiments were done in triplicate. *p,0.05 vs. siNEG.
Solid line (&): siNEG; dashed line (m): siEC-SOD *p,0.05 vs. siNEG E. Apoptosis was assayed using the Guava Nexin kit (Guava Technologies)
according to the manufacturer’s protocol. Fluorescence emission for Annexin V staining and 7-AAD was measured by flow cytometry. Experiments
were done in triplicate. *p,0.05 vs. siNEG.
doi:10.1371/journal.pone.0027531.g008
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response to XO. This was supported by our finding in human
PASMC in which knock-down of EC-SOD increased Egr-1
mRNA and protein. In the bovine cell culture model, pretreat-
ment with both SOD and catalase was required to fully block the
XO-induced signal. This indicates that H2O2, which also will
increase with XO treatment due to the rapid dismutation of O2
.2
or its direct generation of H2O2, was capable of inducing Egr-1
expression in this system. In contrast, in the human cells, knocked
down of EC-SOD expression was sufficient to increase Egr-1,
consistent with our previous observation in the mouse model, that
overexpression of EC-SOD in the lung blunted the hypoxic
induction of Egr-1 expression[10]. These data demonstrate that
we can use XO as a model to test how extracellular ROS can
regulate Egr-1 mRNA expression; however, we must also consider
the impact of exogenous vs. endogenous sources of ROS and the
model when we interpret the data. Our data support the
conclusion that extracellular O2
.2 may upregulate Egr-1 directly
or following its dismutation to H2O2. Consistent with our cell
culture findings, one published study reported that the exogenous
administration of H2O2 in cardiac cells also increased Egr-1
mRNA and protein expression [39]. In our study when
SOD+catalase was compared to catalase pretreatment alone,
there is a small difference, suggesting that O2
.2 may have an effect
independent of its dismutation to H2O2. It is also possible that EC-
SOD modulates Egr-1 expression by regulating NO bioavailabil-
ity. This mechanism was not tested in this study. Overall, these
data indicate that while the bovine cell culture experiments do not
fully mimic the in vivo setting, extracellular O2
.2, either directly or
indirectly following its dismutation to H2O2, can upregulate Egr-1
in smooth muscle cell, and provides an opportunity to further
understand how O2
.2 can regulate the redox sensitive transcrip-
tion factor, Egr-1.
Published studies have shown enhanced induction of Egr-1 with
hypoxia [10,14–19], For example, fetal bovine pulmonary artery
fibroblasts exhibited an increase in Egr-1 mRNA by Northern blot
analysis following four hours of 3% oxygen [18]. However, we
observed that exposure of PASMCs to hypoxia (1% for 1–
4 hours), in addition to generating lower concentrations of
extracellular O2
.2 than XO, also had a much smaller impact on
Egr-1 mRNA expression. This demonstrates that hypoxic
induction of Egr-1 is specific to tissue or cell types, particularly
given the known heterogeneity in cells within the vessel wall. The
response can also vary with the hypoxic condition and the extent
of hypoxic exposure. We speculate that an important source of
extracellular ROS in the pulmonary circulation is that generated
by recruited or resident inflammatory cells in response to hypoxia.
Thus, a short bolus exposure to hypoxia in a single vascular cell
type does not mimic the in vivo model system. While we focused in
this study on the impact of extracellular O2
.2 on Egr-1 regulation,
our data with antimycin A suggest that under certain conditions,
intracellular ROS production can also modulate the expression of
this transcription factor. Further studies will dissect the origin and
sources of extracellular ROS, distinct from cytosolic or mitochon-
drial sources, in the lung and pulmonary circulation in response to
hypoxia. Since the use of hypoxia in cultured vascular cells was
limited by the low levels of extracellular O2
.2 generated and a
minimal impact on Egr-1 regulation, we selected XO treatment as
a model to test whether extracellular O2
.2 upregulated Egr-1 via
the activation of MAPK pathways.
There is extensive data implicating the MAPK/ERK1/2
pathway in the regulation of Egr-1 and in the pathogenesis of
chronic hypoxic pulmonary hypertension [1,17,18,39–41]. Fur-
thermore, it is well-established that reactive oxygen species can
activate MAPK through its phosphorylation [42]. These two
observations formed the basis of our decision to test whether ROS
generated outside the cell upregulated Egr-1 via MAPK. We
found that extracellular ROS, generated by XO, phosphorylated
ERK1/2, while inhibition of the ERK1/2 pathway prevented the
upregulation of Egr-1. This identifies the importance of MAPK/
ERK pathway in the redox regulation of Egr-1 in neonatal
PASMC. A recent study showed that an increased extracellular
oxidation in vascular smooth muscle cells activated the EGFR
membrane receptor, leading to phosphorylation of ERK1/2 and
activation of downstream transcription factors [43]. Our work thus
provides a basis for future studies to better understand how the
activity of EC-SOD may regulate extracellular redox state and
further dissect its targets leading to ERK1/2 phosphorylation and
regulation of Egr-1. Accordingly, targeting Egr-1 regulation may
represent a novel therapeutic strategy to prevent PA remodeling.
The regulation of Egr-1 has been implicated in vascular
remodeling in a number of models including the calf model of
chronic hypoxic pulmonary hypertension. For example, upregula-
tion of Egr-1 contributes to cyclin D1 expression and hypoxia-
induced cell proliferation in fetal lung fibroblasts and stimulates
insulin-like growth factor-1 receptor, resulting in vascular
remodeling of vein grafts [44]. In addition, a pro-proliferative
and anti-apoptotic phenotype has been attributed to SMC in
pulmonary hypertension. Consistent with these studies, we were
also able to show that knock-down of EC-SOD in human PASMC
upregulated cyclin D1 and ERK1/2 activation, augmented
proliferation and blunted apoptosis, providing direct evidence for
EC-SOD in regulating PASMC phenotype.
In summary, we report that the neonatal calf has low SOD
activity levels in the pulmonary artery and EC-SOD activity
decreases further in the calf with pulmonary hypertension
secondary to chronic hypoxia. The loss of EC-SOD is associated
with an increase in Egr-1 mRNA in the pulmonary artery. We
thus tested the impact of extracellular O2
.2 and its product, H2O2,
on Egr-1 expression in vascular smooth muscle and found that
exogenous production of these ROS, via xanthine oxidase,
upregulated Egr-1. Hypoxia itself had a minimal effect on either
Egr-1 expression or O2
.2 production. Extracellular ROS together
with activation of ERK1/2 by phosphorylation regulated the
increase in Egr-1. Therefore, targeting Egr-1 by controlling
extracellular ROS generation and thereby balancing the cellular
redox status could be a potential therapeutic pathway for
pulmonary artery remodeling. Our data provided new insight
into the role of extracellular O2
.2 and EC-SOD in the
pathogenesis of pulmonary hypertension.
Supporting Information
Figure S1 Total SOD activity is less in the calf lung
compared to the mouse lung. A. Total lung SOD, measured
with an SOD activity kit (Dojindo Molecular Technologies) and
expressed as units of SOD activity per gram tissue (U/g tissue),
compared the activity in control two week old calves to immature
control four week old mice. *p,0.05; n=5. B. Western blot
analysis of calf lung protein (25 mg) and purified bovine EC-SOD
(1 mg) with a rabbit polyclonal EC-SOD antibody quantified. C.
Representative Western blot of total PA homogenates for Cu,Zn
SOD and Mn SOD with densitometry normalized to ß-actin,
n=5–6. p=0.07 between groups for both blots.
(TIF)
Figure S2 Dose response curve and time course for
xanthine oxidase on Egr-1 mRNA expression. A. Calf
PASMC were treated with 0, 1, 4, 8 and 16 mU/mL xanthine
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expression was determined by qPCR. Experiment was performed
in triplicate and data expressed as Egr-1/HPRT relative to control
cells. *p,0.05 vs control. B. Calf PASMC were treated with
8 mU/mL xanthine oxidase+0.5 mM hypoxanthine for 0.5, 1, 2
and 4 hours and Egr-1 mRNA expression was determined by
qPCR. Experiment was performed in triplicate and data expressed
as Egr-1/HPRT relative to vehicle-treated control cells. *p,0.05
vs control.
(TIF)
Figure S3 Combined treatment with SOD and CAT
significantly inhibited XO induced Egr-1 expression.
PASMC were pretreated with SOD (500 U/mL), Cat (600 U/
mL) or combined SOD+CAT for 30 minutes prior to xanthine
oxidase (8 mU/mL) and hypoxanthine (0.5 mM) to evaluate the
contribution of superoxide and hydrogen peroxide to Egr-1
upregulation. mRNA was isolated analyzed by real-time RT-PCR
for Egr-1 and HPRT expression. *p,0.05 vs. Vehicle and
#p,0.05 vs. XO+SOD treatment.
(TIF)
Figure S4 Ponceau S stain of the blot presented in
Figure 7 to demonstrate equal protein loading. The
membrane shown in Figure 7B was stained with Ponceau S to
confirm equal nuclear protein loading.
(TIF)
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